00070 A MULTICENTRE PHASE II TRIAL OF GEFITINIB 500 MG/ DAY IN PATIENTS WITH RECURRENT EGFR-POSITIVE GYNAECOLOGICAL TUMOURS. (1st September 2005) - Vergote, I.; Amant, F.; Forget, F.; Canon, J. L.; Awada, A.; Dirix, L.; Van Belle, S.